Liquid Biopsy Market

Liquid Biopsy Market [Application: Oncology, NIPT, Transplant Diagnostics; Circulating Biomarker: Circulating Tumor Cells (CTC), Free Nucleic Acid, Extracellular Vesicles] – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Market Outlook 2031

  • The global liquid biopsy market size stood at US$ 3.7 Bn in 2022
  • It is expected to increase at a CAGR of 8.8% from 2023 to 2031 and reach US$ 7.7 Bn by the end of 2031

Analyst Viewpoint

Rise in prevalence of cancer, increase in applications of liquid biopsy and growing research on enhancing efficacy of liquid biopsy over other diagnostic tests are estimated to propel the market in 2023. Furthermore, increase in demand for early cancer detection through non-invasive procedures is also likely to fuel the liquid biopsy market demand in the next few years.

Leading companies in liquid biopsy field are collaborating to establish industry-wide standards and comply with stringent regulatory requirements. Moreover, advancements in multi-omics analysis, expansion of liquid biopsy applications to other diseases, and the integration of artificial intelligence for data interpretation are expected to boost the liquid biopsy industry in the next few years.

Liquid Biopsy Market

Market Introduction

Liquid biopsies can improve or resolve several inherent issues with current cancer treatment, enabling early cancer detection, mutation detection, tumor monitoring during treatment. They have the potential to detect cancer before tumor formation, assess multiple mutations within the tumor.

Governments are taking initiatives regarding public screening tests to reduce the further spread of chronic disorders. Non-invasive screening tests help in detection of signs of cancerous tumors inclusive of cell free DNAs, circulating biomarkers, and circulating tumor DNAs (ctDNAs) in cancer patients at recurrent or screening stages. Growing frequency of US FDA-approved advanced tests is expected to drive liquid biopsy market revenue in the next few years.

The ability of liquid biopsies to capture tumor heterogeneity and dynamics, detect MRD at an early stage, assess real-time treatment response, biomarker discovery, and non-invasive nature make liquid biopsy test an invaluable tool in formulating personalized treatment strategies. Liquid biopsy for cancer test also allows for easier accessibility, especially when obtaining tissue biopsies may be challenging or impractical. Therefore, rise in demand for non-invasive diagnostic approaches is anticipated to offer significant liquid biopsy market opportunities in the near future.

Rise in Demand for Non-Invasive Pre-Natal Tests Propelling Liquid Biopsy Market Growth

The non-invasive nature of liquid biopsies eliminates the need for traditional tissue biopsies, reducing patient discomfort and the risk of complications. This makes liquid biopsies particularly appealing for patients who may be reluctant or unable to undergo surgical procedures. Ongoing research is focused on boosting the application of liquid biopsies to population-wide cancer screening programs. The potential for early detection of cancer in asymptomatic individuals could significantly impact cancer mortality rates.

Demand for non-invasive prenatal testing is considerably high due to an increase in number of congenital and genetic abnormalities in the fetus. According to an article published by the UN group, in Arch 2022, nearly 3000 to 5000 children are born with Down syndrome annually. In May 2021, Yourgene announced the launch of IONA care – a NIPT service offering.

This solution provides an extended advantage to measure the probability that a pregnant woman is carrying fetus with autosomal aneuploidies (AA2) and sex chromosome aneuploidies (SCA1) apart from screening for trisomies 13, 18 and 21 and fetal sex determination. Thus, growing awareness about the importance of prenatal testing is expected to fuel the liquid biopsy market development in the next few years.

Increase in Investments in Clinical Trials by Manufacturers Augmenting Liquid Biopsy Market Demand

Currently, technology advancements in liquid biopsies are driving the frequency of therapeutic selection, cancer screening, recurrence monitoring, and drug trial optimization. Several government agencies, in collaboration with key players, are emphasizing investment in R&D to conduct clinical studies on liquid biopsy for offering precision medicine for patients.

In November 2021, BioMark Diagnostics, Inc. received funding close to US$ 135,640 from National Research Council of Canada Industrial Research Assistance Program (NRCIRAP). The basic purpose of this funding was to extend support to R&D of liquid biopsy assay to screen and detect lung cancer at early stages.

In November 2022, Thermo Fisher Scientific tabled digital PCR liquid-biopsy assays for Applied Biosystems absolute Q dPCR system and custom design tool for simplifying cancer research in clinical research and academic institutes.

Investments in liquid biopsy testing for early cancer detection have been rising for the last few years, as it provides valuable insights into the molecular characteristics of tumors, enabling the tailoring of cancer treatments based on individual genetic profiles. This personalized approach holds promise for more effective and targeted therapies and is consequently expected to bolster the global liquid biopsy market development during the forecast period.

Liquid Biopsy Market Regional Insights

North America accounted for the largest liquid biopsy market share in 2022 due to growing incidence of cancer and rapid advancements in screening technology in the region. As per the American Cancer Society, 1.9 million cancer cases with 609,360 fatalities were recorded in the U.S in 2022. Several organizations such as the American Society of Clinical Oncology (ASCO) are working on creating awareness campaigns regarding utilization of various types of liquid biopsy tests for early cancer detection.

According to the latest market analysis, growing awareness about prenatal screening and early cancer detection among the population is estimated to positively impact the liquid biopsy market outlook in Europe in the next few years.

Governments across Europe are taking initiatives to boost cancer screening along with various other pathology tests. In March 2022, the U.K. National health Service offered liquid biopsy tests to some cancer patients for complementing anatomic pathology testing with an effort of diagnosing 75% of all kinds of cancer at stage I or stage II by 2028. Moreover, as per the data by published by MDPI in 2022, close to 6,560 patients benefit from liquid biopsy tests every year.

Analysis of Key Players

Leading companies are following the latest liquid biopsy market trends and focusing on research and development initiatives, strategic collaborations, and the commercialization of advanced liquid biopsy technologies. Key players are engaged in organic as well as inorganic modes of expansion to strengthen their global presence. Biocept, Inc., MDxHealth, Myriad Genetics, Inc., Bio-Rad Laboratories, QIAGEN, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Genomic Health, Inc., and Illumina, Inc. are a few prominent entities operating in the global market.

Key Developments

  • In November 2023, Illumina Inc. announced the launch of TruSight Oncology 500 ctDNA v2, a novel generation of liquid biopsy assay to enable genomic profiling
  • In January 2023, Agilent Technologies, Inc. completed the acquisition of Avida Biomed with the objective of expanding in the market for diagnostic and clinical research
  • In December 2022, Menarini Silicon Biosystems, Inc. conducted a clinical study in collaboration with Dana-Farber cancer institute. It showed potential for minimally invasive management of those diagnosed with multiple myeloma. CELLSEARCH system was the result of this collaboration.
  • In December 2022, Guardant Health, Inc. entered into a partnership with Susan G. Komen for conducting clinical studies to identify patients suffering from breast cancer through Guardant Reveal, a blood-based test
  • In August 2022, Predicine introduced the CE-Market Predicine CARE for PredicineCARE ‒ a liquid biopsy for genomic profiling. The purpose was to focus on 152 genes in those diagnosed with cancer.

Key players in the liquid biopsy market report have been profiled based on various parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Liquid Biopsy Market Snapshot

Attribute Detail
Size in 2022 US$ 3.7 Bn
Forecast (Value) in 2031 US$ 7.7 Bn
Growth Rate (CAGR) 8.8%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Application
    • Oncology
    • NIPT
    • Transplant Diagnostics
    • Others
  • Circulating Biomarker
    • Circulating Tumor Cells (CTC)
    • Free Nucleic Acid
    • Extracellular Vesicles/Exosomes
  • End-user
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Sales
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
Companies Profiled
  • Biocept, Inc.
  • MDxHealth
  • Myriad Genetics, Inc.
  • Bio-Rad Laboratories
  • QIAGEN
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific, Inc.,
  • Genomic Health, Inc.
  • Illumina, Inc.
Customization Scope Available Upon Request
Pricing Available Upon Request

Frequently Asked Questions

How big was the liquid biopsy market in 2022?

The global market was valued at US$ 3.7 Bn in 2022

How is liquid biopsy industry expected to grow during the forecast period?

It is projected to grow at a CAGR of 8.8% from 2023 to 2031

What are the key factors driving the demand for liquid biopsy?

Rise in demand for non-invasive pre-natal tests and increase in investments in clinical trials

Which liquid biopsy segment held the largest share in 2022?

In terms of end-user, the hospitals segment held largest share in 2022

Which region is expected to dominate the liquid biopsy business?

North America is estimated to dominate in the next few years

Who are the key liquid biopsy providers?

Biocept, Inc., MDxHealth, Myriad Genetics, Inc., Bio-Rad Laboratories, QIAGEN, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Genomic Health, Inc., and Illumina, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions

    3. Research Methodology

    4. Executive Summary

    5. Market Overview

        5.1. Introduction

        5.2. Market Dynamics

            5.2.1. Drivers

            5.2.2. Restraints

            5.2.3. Opportunities

        5.3. Key Trends Analysis

            5.3.1. Demand Side Analysis

            5.3.2. Supply Side Analysis

        5.4. Key Market Indicators

        5.5. Technological Overview Analysis

        5.6. Porter’s Five Forces Analysis

        5.7. Industry SWOT Analysis

        5.8. Value Chain Analysis

        5.9. Regulatory Framework

        5.10. Global Liquid Biopsy Market Analysis and Forecast, - 2017–2031

            5.10.1. Market Value Projections (US$ Mn)

    6. Global Liquid Biopsy Market Analysis and Forecast, by Application

        6.1. Liquid Biopsy Market Size (US$ Mn) Forecast, by Application, 2017–2031

            6.1.1. Oncology

            6.1.2. NIPT

            6.1.3. Transplant Diagnostics

            6.1.4. Others

        6.2. Incremental Opportunity, by Application

    7. Global Liquid Biopsy Market Analysis and Forecast, by Circulating Biomarker

        7.1. Liquid Biopsy Market Size (US$ Mn) Forecast, by Circulating Biomarker, 2017–2031

            7.1.1. Circulating Tumor Cells (CTC)

            7.1.2. Free Nucleic Acid

            7.1.3. Exracellular Vesicles/Exosomes

        7.2. Incremental Opportunity, by Circulating Biomarker

    8. Global Liquid Biopsy Market Analysis and Forecast, by End-user

        8.1. Liquid Biopsy Market Size (US$ Mn) Forecast, End-user, 2017–2031

            8.1.1. Hospitals

            8.1.2. Reference Laboratories

            8.1.3. Academic and Research Institutes

            8.1.4. Others

        8.2. Incremental Opportunity, by End-user

    9. Global Liquid Biopsy Market Analysis and Forecast, by Region

        9.1. Liquid Biopsy Market Size (US$ Mn) Forecast, by Region, 2017–2031

            9.1.1. North America

            9.1.2. Europe

            9.1.3. Asia Pacific

            9.1.4. Middle East & Africa

            9.1.5. South America

        9.2. Incremental Opportunity, by Region

    10. North America Liquid Biopsy Market Analysis and Forecast

        10.1. Regional Snapshot

        10.2. Brand Analysis

        10.3. Price Trend Analysis

            10.3.1. Weighted Average Price

        10.4. Key Trends Analysis

            10.4.1. Demand Side

            10.4.2. Supplier Side

        10.5. Liquid Biopsy Market Size (US$ Mn) Forecast, by Application, 2017–2031

            10.5.1. Oncology

            10.5.2. NIPT

            10.5.3. Transplant Diagnostics

            10.5.4. Others

        10.6. Liquid Biopsy Market Size (US$ Mn) Forecast, by Circulating Biomarker, 2017–2031

            10.6.1. Circulating Tumor Cells (CTC)

            10.6.2. Free Nucleic Acid

            10.6.3. Exracellular Vesicles/Exosomes

        10.7. Liquid Biopsy Market Size (US$ Mn) Forecast, End-user - 2017–2031

            10.7.1. Hospitals

            10.7.2. Reference Laboratories

            10.7.3. Academic and Research Institutes

            10.7.4. Others

        10.8. Liquid Biopsy Market Size (US$ Mn) Forecast, by Country - 2017–2031

            10.8.1. U.S.

            10.8.2. Canada

            10.8.3. Rest of North America

        10.9. Incremental Opportunity Analysis

    11. Europe Liquid Biopsy Market Analysis and Forecast

        11.1. Regional Snapshot

        11.2. Brand Analysis

        11.3. Price Trend Analysis

            11.3.1. Weighted Average Price

        11.4. Key Trends Analysis

            11.4.1. Demand Side

            11.4.2. Supplier Side

        11.5. Liquid Biopsy Market Size (US$ Mn) Forecast, by Application, 2017–2031

            11.5.1. Oncology

            11.5.2. NIPT

            11.5.3. Transplant Diagnostics

            11.5.4. Others

        11.6. Liquid Biopsy Market Size (US$ Mn) Forecast, by Circulating Biomarker, 2017–2031

            11.6.1. Circulating Tumor Cells (CTC)

            11.6.2. Free Nucleic Acid

            11.6.3. Exracellular Vesicles/Exosomes

        11.7. Liquid Biopsy Market Size (US$ Mn) Forecast, End-user, 2017–2031

            11.7.1. Hospitals

            11.7.2. Reference Laboratories

            11.7.3. Academic and Research Institutes

            11.7.4. Others

        11.8. Liquid Biopsy Market Size (US$ Mn) Forecast, by Country, 2017–2031

            11.8.1. U.K.

            11.8.2. Germany

            11.8.3. France

            11.8.4. Rest of Europe

        11.9. Incremental Opportunity Analysis

    12. Asia Pacific Liquid Biopsy Market Analysis and Forecast

        12.1. Regional Snapshot

        12.2. Brand Analysis

        12.3. Price Trend Analysis

            12.3.1. Weighted Average Price

        12.4. Key Trends Analysis

            12.4.1. Demand Side

            12.4.2. Supplier Side

        12.5. Liquid Biopsy Market Size (US$ Mn) Forecast, by Application, 2017–2031

            12.5.1. Oncology

            12.5.2. NIPT

            12.5.3. Transplant Diagnostics

            12.5.4. Others

        12.6. Liquid Biopsy Market Size (US$ Mn) Forecast, by Circulating Biomarker, 2017–2031

            12.6.1. Circulating Tumor Cells (CTC)

            12.6.2. Free Nucleic Acid

            12.6.3. Exracellular Vesicles/Exosomes

        12.7. Liquid Biopsy Market Size (US$ Mn) Forecast, End-user, 2017–2031

            12.7.1. Hospitals

            12.7.2. Reference Laboratories

            12.7.3. Academic and Research Institutes

            12.7.4. Others

        12.8. Liquid Biopsy Market Size (US$ Mn) Forecast, by Country, 2017–2031

            12.8.1. India

            12.8.2. China

            12.8.3. Japan

            12.8.4. Rest of Asia Pacific

        12.9. Incremental Opportunity Analysis

    13. Middle East & South Africa Liquid Biopsy Market Analysis and Forecast

        13.1. Regional Snapshot

        13.2. Brand Analysis

        13.3. Price Trend Analysis

            13.3.1. Weighted Average Price

        13.4. Key Trends Analysis

            13.4.1. Demand Side

            13.4.2. Supplier Side

        13.5. Liquid Biopsy Market Size (US$ Mn) Forecast, by Application, 2017–2031

            13.5.1. Oncology

            13.5.2. NIPT

            13.5.3. Transplant Diagnostics

            13.5.4. Others

        13.6. Liquid Biopsy Market Size (US$ Mn) Forecast, by Circulating Biomarker, 2017–2031

            13.6.1. Circulating Tumor Cells (CTC)

            13.6.2. Free Nucleic Acid

            13.6.3. Exracellular Vesicles/Exosomes

        13.7. Liquid Biopsy Market Size (US$ Mn) Forecast, End-user, 2017–2031

            13.7.1. Hospitals

            13.7.2. Reference Laboratories

            13.7.3. Academic and Research Institutes

            13.7.4. Others

        13.8. Liquid Biopsy Market Size (US$ Mn) Forecast, by Country, 2017–2031

            13.8.1. GCC

            13.8.2. Rest of Middle East & Africa

        13.9. Incremental Opportunity Analysis

    14. South America Liquid Biopsy Market Analysis and Forecast

        14.1. Regional Snapshot

        14.2. Brand Analysis

        14.3. Price Trend Analysis

            14.3.1. Weighted Average Price

        14.4. Key Trends Analysis

            14.4.1. Demand Side

            14.4.2. Supplier Side

        14.5. Liquid Biopsy Market Size (US$ Mn) Forecast, by Application, 2017–2031

            14.5.1. Oncology

            14.5.2. NIPT

            14.5.3. Transplant Diagnostics

            14.5.4. Others

        14.6. Liquid Biopsy Market Size (US$ Mn) Forecast, by Circulating Biomarker, 2017–2031

            14.6.1. Circulating Tumor Cells (CTC)

            14.6.2. Free Nucleic Acid

            14.6.3. Exracellular Vesicles/Exosomes

        14.7. Liquid Biopsy Market Size (US$ Mn) Forecast, End-user, 2017–2031

            14.7.1. Hospitals

            14.7.2. Reference Laboratories

            14.7.3. Academic and Research Institutes

            14.7.4. Others

        14.8. Liquid Biopsy Market Size (US$ Mn) Forecast, by Country, 2017–2031

            14.8.1. Brazil

            14.8.2. Rest of South America

        14.9. Incremental Opportunity Analysis

    15. Competition Landscape

        15.1. Market Player - Competition Dashboard

        15.2. Market Share Analysis (%), by Company, (2022)

        15.3. Company Profiles (Details - Company Overview, Sales Area/Geographical Presence, Revenue, Strategy & Business Overview)

            15.3.1. Biocept, Inc.

                15.3.1.1. Company Overview

                15.3.1.2. Sales Area

                15.3.1.3. Geographical Presence

                15.3.1.4. Revenue

                15.3.1.5. Strategy & Business Overview

            15.3.2. MDxHealth

                15.3.2.1. Company Overview

                15.3.2.2. Sales Area

                15.3.2.3. Geographical Presence

                15.3.2.4. Revenue

                15.3.2.5. Strategy & Business Overview

            15.3.3. Myriad Genetics, Inc.

                15.3.3.1. Company Overview

                15.3.3.2. Sales Area

                15.3.3.3. Geographical Presence

                15.3.3.4. Revenue

                15.3.3.5. Strategy & Business Overview

            15.3.4. Bio-Rad Laboratories

                15.3.4.1. Company Overview

                15.3.4.2. Sales Area

                15.3.4.3. Geographical Presence

                15.3.4.4. Revenue

                15.3.4.5. Strategy & Business Overview

            15.3.5. QIAGEN

                15.3.5.1. Company Overview

                15.3.5.2. Sales Area

                15.3.5.3. Geographical Presence

                15.3.5.4. Revenue

                15.3.5.5. Strategy & Business Overview

            15.3.6. F. Hoffmann-La Roche Ltd.

                15.3.6.1. Company Overview

                15.3.6.2. Sales Area

                15.3.6.3. Geographical Presence

                15.3.6.4. Revenue

                15.3.6.5. Strategy & Business Overview

            15.3.7. Thermo Fisher Scientific, Inc.

                15.3.7.1. Company Overview

                15.3.7.2. Sales Area

                15.3.7.3. Geographical Presence

                15.3.7.4. Revenue

                15.3.7.5. Strategy & Business Overview

            15.3.8. Genomic Health, Inc.

                15.3.8.1. Company Overview

                15.3.8.2. Sales Area

                15.3.8.3. Geographical Presence

                15.3.8.4. Revenue

                15.3.8.5. Strategy & Business Overview

            15.3.9. Illumina, Inc.

                15.3.9.1. Company Overview

                15.3.9.2. Sales Area

                15.3.9.3. Geographical Presence

                15.3.9.4. Revenue

                15.3.9.5. Strategy & Business Overview

            15.3.10. Other Key Players

                15.3.10.1. Company Overview

                15.3.10.2. Sales Area

                15.3.10.3. Geographical Presence

                15.3.10.4. Revenue

                15.3.10.5. Strategy & Business Overview

    16. Go to Market Strategy

    17. Identification of Potential Market Spaces

    18. Prevailing Market Risks

    19. Understanding Buying Process of Customers

    20. Preferred Sales & Marketing Strategy

    List of Tables

    Table 1: Global Liquid Biopsy Market Value (US$ Mn), by Application, 2017-2031

    Table 2: Global Liquid Biopsy Market Value (US$ Mn), by Circulating Biomarker, 2017-2031

    Table 3: Global Liquid Biopsy Market Value (US$ Mn), by End-user, 2017-2031

    Table 4: Global Liquid Biopsy Market Value (US$ Mn), by Region, 2017-2031

    Table 5: North America Liquid Biopsy Market Value (US$ Mn), by Application, 2017-2031

    Table 6: North America Liquid Biopsy Market Value (US$ Mn), by Circulating Biomarker, 2017-2031

    Table 7: North America Liquid Biopsy Market Value (US$ Mn), by End-user, 2017-2031

    Table 8: North America Liquid Biopsy Market Value (US$ Mn), by Region, 2017-2031

    Table 9: Europe Liquid Biopsy Market Value (US$ Mn), by Application, 2017-2031

    Table 10: Europe Liquid Biopsy Market Value (US$ Mn), by Circulating Biomarker, 2017-2031

    Table 11: Europe Liquid Biopsy Market Value (US$ Mn), by End-user, 2017-2031

    Table 12: Europe Liquid Biopsy Market Value (US$ Mn), by Region, 2017-2031

    Table 13: Asia Pacific Liquid Biopsy Market Value (US$ Mn), by Application, 2017-2031

    Table 14: Asia Pacific Liquid Biopsy Market Value (US$ Mn), by Circulating Biomarker, 2017-2031

    Table 15: Asia Pacific Liquid Biopsy Market Value (US$ Mn), by End-user, 2017-2031

    Table 16: Asia Pacific Liquid Biopsy Market Value (US$ Mn), by Region, 2017-2031

    Table 17: Middle East & Africa Liquid Biopsy Market Value (US$ Mn), by Application, 2017-2031

    Table 18: Middle East & Africa Liquid Biopsy Market Value (US$ Mn), by Circulating Biomarker, 2017-2031

    Table 19: Middle East & Africa Liquid Biopsy Market Value (US$ Mn), by End-user, 2017-2031

    Table 20: Middle East & Africa Liquid Biopsy Market Value (US$ Mn), by Region, 2017-2031

    Table 21: South America Liquid Biopsy Market Value (US$ Mn), by Application, 2017-2031

    Table 22: South America Liquid Biopsy Market Value (US$ Mn), by Circulating Biomarker, 2017-2031

    Table 23: South America Liquid Biopsy Market Value (US$ Mn), by End-user, 2017-2031

    Table 24: South America Liquid Biopsy Market Value (US$ Mn), by Region, 2017-2031

    List of Figures

    Figure 1: Global Liquid Biopsy Market Value (US$ Mn), by Application, 2017-2031

    Figure 2: Global Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Application, 2023-2031

    Figure 3: Global Liquid Biopsy Market Value (US$ Mn), by Circulating Biomarker, 2017-2031

    Figure 4: Global Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Circulating Biomarker, 2023-2031

    Figure 5: Global Liquid Biopsy Market Value (US$ Mn), by End-user, 2017-2031

    Figure 6: Global Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by End-user, 2023-2031

    Figure 7: Global Liquid Biopsy Market Value (US$ Mn), by Region, 2017-2031

    Figure 8: Global Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Region, 2023-2031

    Figure 9: North America Liquid Biopsy Market Value (US$ Mn), by Application, 2017-2031

    Figure 10: North America Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Application, 2023-2031

    Figure 11: North America Liquid Biopsy Market Value (US$ Mn), by Circulating Biomarker, 2017-2031

    Figure 12: North America Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Circulating Biomarker, 2023-2031

    Figure 13: North America Liquid Biopsy Market Value (US$ Mn), by End-user, 2017-2031

    Figure 14: North America Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by End-user, 2023-2031

    Figure 15: North America Liquid Biopsy Market Value (US$ Mn), by Region, 2017-2031

    Figure 16: North America Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Region, 2023-2031

    Figure 17: Europe Liquid Biopsy Market Value (US$ Mn), by Application, 2017-2031

    Figure 18: Europe Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Application, 2023-2031

    Figure 19: Europe Liquid Biopsy Market Value (US$ Mn), by Circulating Biomarker, 2017-2031

    Figure 20: Europe Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Circulating Biomarker, 2023-2031

    Figure 21: Europe Liquid Biopsy Market Value (US$ Mn), by End-user, 2017-2031

    Figure 22: Europe Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by End-user, 2023-2031

    Figure 23: Europe Liquid Biopsy Market Value (US$ Mn), by Region, 2017-2031

    Figure 24: Europe Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Region, 2023-2031

    Figure 25: Asia Pacific Liquid Biopsy Market Value (US$ Mn), by Application, 2017-2031

    Figure 26: Asia Pacific Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Application, 2023-2031

    Figure 27: Asia Pacific Liquid Biopsy Market Value (US$ Mn), by Circulating Biomarker, 2017-2031

    Figure 28: Asia Pacific Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Circulating Biomarker, 2023-2031

    Figure 29: Asia Pacific Liquid Biopsy Market Value (US$ Mn), by End-user, 2017-2031

    Figure 30: Asia Pacific Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by End-user, 2023-2031

    Figure 31: Asia Pacific Liquid Biopsy Market Value (US$ Mn), by Region, 2017-2031

    Figure 32: Asia Pacific Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Region, 2023-2031

    Figure 33: Middle East & Africa Liquid Biopsy Market Value (US$ Mn), by Application, 2017-2031

    Figure 34: Middle East & Africa Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Application, 2023-2031

    Figure 35: Middle East & Africa Liquid Biopsy Market Value (US$ Mn), by Circulating Biomarker, 2017-2031

    Figure 36: Middle East & Africa Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Circulating Biomarker, 2023-2031

    Figure 37: Middle East & Africa Liquid Biopsy Market Value (US$ Mn), by End-user, 2017-2031

    Figure 38: Middle East & Africa Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by End-user, 2023-2031

    Figure 39: Middle East & Africa Liquid Biopsy Market Value (US$ Mn), by Region, 2017-2031

    Figure 40: Middle East & Africa Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Region, 2023-2031

    Figure 41: South America Liquid Biopsy Market Value (US$ Mn), by Application, 2017-2031

    Figure 42: South America Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Application, 2023-2031

    Figure 43: South America Liquid Biopsy Market Value (US$ Mn), by Circulating Biomarker, 2017-2031

    Figure 44: South America Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Circulating Biomarker, 2023-2031

    Figure 45: South America Liquid Biopsy Market Value (US$ Mn), by End-user, 2017-2031

    Figure 46: South America Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by End-user, 2023-2031

    Figure 47: South America Liquid Biopsy Market Value (US$ Mn), by Region, 2017-2031

    Figure 48: South America Liquid Biopsy Market Incremental Opportunity (US$ Mn), Forecast, by Region, 2023-2031

Copyright © Transparency Market Research, Inc. All Rights reserved